Roche vaults in­to lead in front­line triple neg­a­tive breast can­cer as Tecen­triq/Abrax­ane com­bo aces pro­gres­sion-free sur­vival

Fast on the heels of a key suc­cess for small cell lung can­cer, Roche’s Tecen­triq team at Genen­tech has scored an­oth­er front­line win for the phar­ma gi­ant.

This time the in­ves­ti­ga­tors say that Tecen­triq com­bined with Cel­gene’s Abrax­ane sig­nif­i­cant­ly im­proved pro­gres­sion-free sur­vival in triple neg­a­tive breast can­cer — a first in the field.

We don’t know the da­ta, which are be­ing held for a fu­ture con­fer­ence. But the suc­cess here puts Roche at the goal line with ap­pli­ca­tions be­ing read­ied for the FDA and the EMA — with a high per­cent­age shot at suc­cess.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.